Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia (TOSCA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04332913 |
|
Recruitment Status : Unknown
Verified April 2020 by Prof. Roberto Giacomelli, University of L'Aquila.
Recruitment status was: Recruiting
First Posted : April 3, 2020
Last Update Posted : April 13, 2020
|
Sponsor:
University of L'Aquila
Information provided by (Responsible Party):
Prof. Roberto Giacomelli, University of L'Aquila
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The current spread of the COrona VIrus Disease-2019 (COVID-19) epidemic in Italy, and the current lack of effective and approved drugs for its treatment, poses the problem of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients management, especially those who underwent to experience COVID-19 complications, such as CRS. This unmet need becomes more severe if the investigator consider that, the COVID-19 mortality stands around 2% in the general population, but it rises to 49% when considering intensive care unit (ICU) patients. To increase the chances of survival of these patients, the compassionate use of the available drugs is required, based on literature data, to the best of our abilities. ICU patients with cytokine release syndrome (CRS) secondary to COVID-19, show increased production of pro-inflammatory cytokines, including interleukin (IL-6), IL-2, IL-7, IL-10, tumor necrosis factor (TNF)-α and interferon (INF)γ, similar to that found in patients who develop CRS secondary to Chimeric Antigen Receptor-T (CAR-T) therapy. Although immuno-modulatory therapy is not routinely recommended in COVID-19 pneumonia, tocilizumab might have a rationale in those patients who develop CRS, blocking the complications caused by high levels of IL-6, and possibly preventing the development of a multi-organ failure. Reassuring data in this sense, come from the first studies conducted in China. In a Chinese pilot study, Xiaoling Xu and collaborators used tocilizumab (at a dosage of 400 mg iv in a single dose, with a possible second dose in case of no clinical response) in patients with COVID-19 in the presence of one of the following criteria: i) respiratory rate ≥ 30 acts/min; ii) SpO2 ≤ 93% in ambient air; iii) PaO2/FiO2 ≤ 300 mmHg. In the 21 patients treated with tocilizumab a significant reduction in IL-6 levels and fever, with improvement in lung function, was demonstrated. Besides, 90% of treated patients showed an improvement in the radiological picture, in terms of a decrease in the frosted glass areas, and a return to normal lymphocytes count in the peripheral blood. This is a prospective observational clinical study and it is aimed at verifying tocilizumab efficacy and safety in patients with COVID-19 complicated by acute distress respiratory syndrome (ARDS) and CRS.
| Condition or disease |
|---|
| COVID-19 Pneumonia |
| Study Type : | Observational |
| Estimated Enrollment : | 30 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study |
| Estimated Study Start Date : | April 1, 2020 |
| Estimated Primary Completion Date : | December 31, 2020 |
| Estimated Study Completion Date : | March 31, 2021 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Tocilizumab
Primary Outcome Measures :
- Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab. [ Time Frame: 14 days ]Fever normalization criteria: Temperature <36.6 ° C for at least 72 hours; SpO2 normalization criterion: SpO2> 94% for at least 72 hours
Secondary Outcome Measures :
- Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration. [ Time Frame: 24 hours ]
- Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab. [ Time Frame: 14 days ]Fever normalization criteria: Temperature <36.6 ° C for at least 72 hours
- Duration of hospitalization [ Time Frame: 14 days ]days
- Time to the first negative SARS-CoV-2 negative RT-PCR test [ Time Frame: 14 days ]days
- Changes from the baseline in the white blood cell count [ Time Frame: 7, 14 days ]number/microliter
- Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17) [ Time Frame: 7, 14 days ]number/microliter
- Changes from the baseline of c-reactive protein (CRP) values [ Time Frame: 7, 14 days ]
- Changes from the baseline of Ferritin values [ Time Frame: 7, 14 days ]
- Changes from the baseline of BNP values [ Time Frame: 7,14 days ]
- Changes from the baseline of CK-MB values [ Time Frame: 7,14 days ]
- Changes from the baseline of Troponin values [ Time Frame: 7,14 days ]
- Changes from the baseline of LDH values [ Time Frame: 7,14 days ]
- Changes from the baseline of myoglobulin values [ Time Frame: 7,14 days ]
- Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO) [ Time Frame: 7,14 days ](ST segments elevation or depression, T-wave changes)
- Rate of adverse events report during and after tocilizumab [ Time Frame: 14 days ]
- Mortality (number of Partecipants, cause and timing) [ Time Frame: 12 weeks ]
- Percentage of patients who develop autoimmune diseases [ Time Frame: 1 year ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Sampling Method: | Probability Sample |
Study Population
COVID-19 patients with pneumonia requiring hospitalization
Criteria
Inclusion Criteria:
- All gender patients aged ≥ 18 years;
- Patients with SARS-CoV-2 infection confirmed by tests (RT-PCR) and pulmonary involvement, hospitalized, at the end of the initial phase of high viral load of COVID-19 (apyretic> 72 hours and / or at least 7 days after onset of symptoms);
- Worsening of respiratory exchanges such as to require non-invasive or invasive ventilation support (BCRSS score ≥ 3).
- High levels of IL-6 (> 40 pg/mL) or alternatively CRP and/or ferritin and/or D-dimer and/or fibrinogen values higher than the reference values or rapidly increasing;
- Signature of informed consent.
Exclusion Criteria:
- Alanine aminotransferase and/or Aspartate aminotransferase (ALT / AST) > 5 times compared to normal laboratory values.
- Presence of a chronic renal failure ≥ 4 stage (glomerular filtrate values <30 ml/min/1.73 m2).
- Presence of neutropenia (neutrophils count < 500 / mm3).
- Platelet count less than 50 x 103/μL.
- Documented sepsis from other pathogens other than SARS-CoV-2.
- Presence of co-morbidities associated, in clinical judgment, with an unfavourable outcome.
- Complicated diverticulitis and / or intestinal perforation.
- Skin infection in progress (e.g. dermohypodermitis not controlled by antibiotic therapy).
- Immuno-suppressive anti-rejection therapy.
- Pregnancy or woman of childbearing age who does not use contraceptive and/or breastfeeding measures.
- Previous ischemic attack or myocardial infarction.
- NYHA class III or IV heart failure.
- Severe depressive syndrome or other psychiatric disease which, in the opinion of the doctor, can preclude patient participation in the study.
- Presence of known malignant neoplasms.
- Clinically significant history of alcohol abuse or drug addiction which, in the opinion of the doctor, may preclude the subject's participation in the study.
- Any condition which, in the opinion of the doctor, precludes the possibility of using the study drug provided for in the RCP.
- Any other laboratory condition or parameter that, in the doctor's judgment, precludes the subject's participation in the study.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04332913
Contacts
| Contact: Roberto Giacomelli, MD, PhD | 0039 0862 434742 | roberto.giacomelli@univaq.it |
Locations
| Italy | |
| Ospedale San Salvatore | Recruiting |
| L'Aquila, Italy, 67100 | |
| Contact: Roberto Giacomelli, MD 0862434742 roberto.giacomelli@univaq.it | |
Sponsors and Collaborators
University of L'Aquila
Publications of Results:
Other Publications:
Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the Coronavirus Study Group. BioRxivchinaXiv:202003.00026v172020:2020.02.07.937862.
Other Publications:
| Responsible Party: | Prof. Roberto Giacomelli, Full Professor, University of L'Aquila |
| ClinicalTrials.gov Identifier: | NCT04332913 |
| Other Study ID Numbers: |
0064468/20 |
| First Posted: | April 3, 2020 Key Record Dates |
| Last Update Posted: | April 13, 2020 |
| Last Verified: | April 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
Keywords provided by Prof. Roberto Giacomelli, University of L'Aquila:
|
Tocilizumab |
Additional relevant MeSH terms:
|
COVID-19 Pneumonia Respiratory Tract Infections Infections Pneumonia, Viral Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |